At its highest dose, 36 mg, participants in a phase 3 trial lost an average of 12.4 percent of their starting weight over 72 weeks
Mounjaro heeft daarnaast een extra effect door de activatie van de GIP-receptor, wat het metabolisme verder ondersteunt
Currently available only within Phase 3 clinical trials, retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, distinguishing it from approved therapies such as semaglutide and tirzepatide
This promotes a feeling of fullness and may help with weight management
This also depends on how your body reacts to the medication, but clinical trials showed that after 24 weeks (around six months), the average participant on higher doses of retatrutide lost close to 18% of their body weight